Fertility-Sparing Treatment in Gestational Choriocarcinoma: Evaluating Oncological and Obstetrical Outcomes in Young Patients

14 November 2023 : Clinical Research

Szymon Piątek

^1ABCDEF*, Natalia Szczęsny

^2BE, Iwona Szymusik

^3EF, Karolina Karoń^2BE, Krzysztof Piątkowski^2BE, Ewelina Bornio

^2BE, Mariusz Bidziński

^1EF, Mariusz Gujski

^4E

DOI: 10.12659/MSM.942078

Med Sci Monit 2023; 29:e942078

Table 1 Patients’ characteristics.

Patient	Age (years)	Antecedent pregnancy	Uterus lesion	FIGO stage	FIGO score (points)	Pretreatment Beta-hCG (mIU/mL)	Chemotherapy regimen/number of cycles	Response/salvage therapy for non-responders	Recurrence	Childbirth after treatment (time since diagnosis)
1.	30	No	No	III	8	100821	EMACO/7	CR	No	No
2.	30	Birth	No	IV	11	10371	EMACO/7	CR	No	No
3.	30	Birth	No	III	6	20511	MTX/6	CR	No	Yes (46 months)
4.	33	Abortion	Yes	I	6	12260	MTX/3	Progression/hysterectomy+ EMACO	No	No
5.	30	Birth	Yes	III	7	23728	EMACO/5	CR	No	No
6.	24	Birth	Yes	IV	12	213.9	EMACO/5	CR	Yes (after 62 moths)/hysterectomy+ EMACO	No
7.	34	Birth	Yes	III	5	29168	MTX/6	CR	No	No
8.	32	Mole	Yes	I	0	172.9	MTX/7	Progression/EMACO	No	No
9.	25	Mole	Yes	I	0	42	MTX/2	Progression/EMACO	No	Yes (39 months)
10.	29	Mole	Yes	I	5	2673	MTX/5	CR	No	No
11.	24	Mole	Yes	I	2	110613	Actinomycin D/6	CR	No	Yes (35 months and 77 months)
12.	37	Birth	Yes	III	9	7046	EMACO/7	CR	No	No
13.	27	Abortion	Yes	III	8	86441	EMACO/8	CR	No	No
14.	33	Birth	Yes	IV	13	201272	EMACO/6	CR	No	No
15.	26	Abortion	Yes	IV	7	21139	EMACO/6 +brain radiotherapy	CR	No	Yes (41 months and 76 months)
16.	30	Abortion	No	III	1	769	MTX/6	CR	No	No
17.	37	Birth	No	III	13	408179	EMACO/1	Progression, death within 1 month	–	–
18.	40	Mole	Yes	III	12	871940	EMACO/3	Progression/hysterectomy, POMB, EMACO; death 3 months since diagnosis	–	–
CR – complete response; MTX – methotrexate; EMACO – etoposide, methotrexate, actinomycin D, cyclophosphamide and vincristine; POMB – cisplatin, vincristine, methotrexate, bleomycin.